COVID KAVACH MERILISA — Anti-SARS-CoV-2 Human IgG ELISA (96T)

COVID KAVACH MERILISA — ICMR-NIV Anti-SARS-CoV-2 Human IgG ELISA

COVID KAVACH MERILISA is intended for qualitative detection of IgG antibodies in serum/plasma of patients presenting clinical signs and symptoms consistent with SARS-CoV-2 infection.

Clinical Background

IgG antibodies generally start appearing after two weeks of onset of infection and persist for several months after recovery. This test can detect past episodes of SARS-CoV-2 infection and is useful for seroprevalence studies.

Key Specifications

• Regulatory: ICMR-NIV validated
• Pack Size: 96 Tests
• Sample Type: Human Serum / Plasma
• Method: Indirect ELISA for IgG antibody detection
• Target Antigen: SARS-CoV-2 spike protein
• Storage: 2–8°C

Ideal for retrospective COVID serology, epidemiological surveys, and immunity assessment post-infection or vaccination.